Piotr Lewczuk heads the Laboratory for Clinical Neurochemistry and Neurochemical Dementia Diagnostics at the Department of Psychiatry and Psychotherapy Universitatsklinikum Erlangen. This lab is one of the mostly internationally recognized European leading centers for neurochemical diagnosis of dementia. The Laboratory is one of the five world-wide reference centers, together with the laboratories in Göteborg (S), Amsterdam (NL), Ghent (B), and Philadelphia (USA), in the Alzheimers Association supported project on CSF biomarkers international quality control. He is a member of the Steering Committee of this project. For more than ten years he has been working on diagnostic and research aspects of the CSF, including a large panel of neurologic and psychiatric disorders with a particular scope on neurodegenerating conditions, like Alzheimers disease.In 2004, he obtained the Certificate of Expertise from the German Society of Clinical Neurochemistry, to become one of seventy certified clinical neurochemists in Germany, and currently he is a member of the Extended Board of the German Society of Clinical Neurochemistry. Dr Lewczuk is also a member of the Scientific Advisory Board of the Alzheimer Diagnostic and Therapy Center at the Medical University of Wroclaw Poland in Scinawa and a consultant of a worldwide leading diagnostic biotech company Innogenetics Ghent Belgium. Piotr Lewczuk heads the Laboratory for Clinical Neurochemistry and Neurochemical Dementia Diagnostics at the Department of Psychiatry and Psychotherapy Universitatsklinikum Erlangen. This lab is one of the mostly internationally recognized European leading centers for neurochemical diagnosis of dementia. The Laboratory is one of the five world-wide reference centers, together with the laboratories in Göteborg (S), Amsterdam (NL), Ghent (B), and Philadelphia (USA), in the Alzheimers Association supported project on CSF biomarkers international quality control. He is a member of the Steering Committee of this project. For more than ten years he has been working on diagnostic and research aspects of the CSF, including a large panel of neurologic and psychiatric disorders with a particular scope on neurodegenerating conditions, like Alzheimers disease.In 2004, he obtained the Certificate of Expertise from the German Society of Clinical Neurochemistry, to become one of seventy certified clinical neurochemists in Germany, and currently he is a member of the Extended Board of the German Society of Clinical Neurochemistry. Dr Lewczuk is also a member of the Scientific Advisory Board of the Alzheimer Diagnostic and Therapy Center at the Medical University of Wroclaw Poland in Scinawa and a consultant of a worldwide leading diagnostic biotech company Innogenetics Ghent Belgium.

Piotr main topics of the current research interest include a) discovery, also in a close cooperation with industrial partners, of novel potential biomarkers of neurodegenerative disorders, and their transfer into clinical routine b) optimization of the analytical performance of the existing biomarkers c) application of multiplexing technologies for the biomarkers discovery and validation d) search for  biomarkers for differential diagnosis among different dementias e) search for possible biomarkers in other body fluids (blood) f) inter- and intra-laboratory quality control issues with special focus on quality management g) organization and management of a large-scale multicenter biobanking of human body fluids.